Skip to main content
. Author manuscript; available in PMC: 2016 Dec 1.
Published in final edited form as: Mol Cancer Ther. 2015 Sep 17;14(12):2773–2781. doi: 10.1158/1535-7163.MCT-15-0243

Table 1.

Numbers of mice bearing MDA-MB-231–LM2-4175 xenografts that had lung metastases after treatment with vehicle (control) or selumetinib (50 mg/kg mouse body weight) daily for 3 weeks.

Weeks of treatment Group of treatment Number of mice with metastatic tumors Incidence of lung metastasis
Week 1 Vehicle 9/15 60
Selumetinib 3/14 21

Week 2 Vehicle 9/14 64
Selumetinib 3/13 23

Week 3 Vehicle 9/14 64
Selumetinib 5/13 38